ARWR

Arrowhead Pharmaceuticals, Inc.

27.30 USD
+1.80 (+7.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arrowhead Pharmaceuticals, Inc. stock is up 9.73% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 23 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 80% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
31 May 15:44 21 Jun, 2024 30.00 PUT 40 1393
03 Jun 14:51 19 Jul, 2024 25.00 PUT 1000 5
03 Jun 17:11 19 Jul, 2024 25.00 PUT 250 5
14 Jun 18:22 20 Sep, 2024 45.00 PUT 18 10
14 Jun 18:22 20 Sep, 2024 45.00 PUT 47 10
17 Jun 13:30 20 Sep, 2024 25.00 CALL 68 2566
20 Jun 18:28 21 Jun, 2024 30.00 PUT 71 485
21 Jun 16:50 21 Jun, 2024 30.00 PUT 90 485
24 Jun 19:19 20 Sep, 2024 45.00 PUT 58 17
24 Jun 19:59 19 Jul, 2024 28.00 CALL 200 10

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.

  • Cantor Fitzgerald
    Thu Jun 20, 13:24
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 11, 13:27
    buy
    confirm
  • Goldman Sachs
    Wed Jun 5, 08:25
    hold
    initial
  • HC Wainwright & Co.
    Mon Jun 3, 13:41
    buy
    confirm
  • Chardan Capital
    Mon Jun 3, 09:41
    buy
    confirm